News

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...
Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.
Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...
Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.
European Commission Approves Biocon Biologics’ Denosumab BiosimilarsBengaluru, Karnataka, India, July 3, 2025 Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary ...
Hyderabad: Aurobindo Pharma has announced that CuraTeQ Biologics, a wholly owned step-down subsidiary of the company, has ...
The European Medicines Agency has revealed a list of five cities that are preferred as its new location by staff after Brexit. Amsterdam, Barcelona, Copenhagen, Milan, or Vienna top staff survey.
Siena: Sun Pharma European partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to ...
CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...
CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.